In preclinical studies, ARV-471 robustly degraded ER in ER+ breast cancer cell lines, suppressed expression of ER-target genes (PR, GREB1, TFF) and inhibited cell proliferation of ER-dependent cell lines (MCF7, T47D) [167]. This evidence concerns the gene ESR1 and breast carcinoma.